Ovarian stimulation with human menopausal and chorionic gonadotropins in a prepubertal hypophysectomized female.
D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D003338:Corpus Luteum / Q000187:drug effects; D003397:Craniopharyngioma / Q000150:complications; D004967:Estrogens / Q000378:metabolism / Q000652:urine; D005260:Female; D006062:Gonadotropins / Q000627:therapeutic use*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D007016:Hypophysectomy / Q000009:adverse effects*; D007018:Hypopituitarism / Q000188:drug therapy*; D008297:Male; D010053:Ovary / Q000187:drug effects*; D010060:Ovulation / Q000187:drug effects; D011276:Pregnanediol / Q000652:urine; D011279:Pregnanetriol / Q000652:urine; D011374:Progesterone / Q000378:metabolism; D011627:Puberty / Q000187:drug effects; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy* / Q000209:etiology; D014621:Vagina / Q000166:cytology
D015068:17-Ketosteroids; D006063:Chorionic Gonadotropin; D004967:Estrogens; D006062:Gonadotropins; D011279:Pregnanetriol; D011374:Progesterone; D011276:Pregnanediol